The effect of iron supplementation in preterm infants at different gestational ages

Sufeng Ruan1, Jinrong Li1, Fei Xiong1

  • 1Department of Pediatrics, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, China.

BMC Pediatrics
|August 20, 2024
PubMed

Insights

Iron supplementation effectively reduces iron deficiency in preterm infants. However, early preterm infants show lower iron levels, suggesting a need for tailored supplementation strategies based on individual factors.

Area of Science:

  • Neonatal nutrition
  • Pediatric hematology
  • Nutritional deficiencies

Background:

  • Iron deficiency (ID) is the most common nutritional deficiency in preterm infants, impacting growth and development.
  • Adequate iron supplementation is critical for the physical and neurological flourishing of preterm infants.
  • This study investigated iron status and growth in preterm infants receiving standard iron supplementation.

Purpose of the Study:

  • To assess if current iron supplementation leads to iron overload in late preterm infants.
  • To determine if current iron supplementation meets catch-up growth needs in early preterm infants.
  • To compare iron deficiency incidence, iron status, and physical growth between early and late preterm infants.

Main Methods:

  • A prospective follow-up study involving 177 preterm infants (January-August 2020).
  • Infants were categorized into early preterm (<34 weeks) and late preterm (≥34 to <37 weeks) groups.
  • Comparison of iron deficiency, iron status, and physical growth in infants receiving 2-4 mg/kg/d iron supplements.

Main Results:

  • Iron supplementation significantly reduced iron deficiency prevalence in both groups.
  • Early preterm infants had lower ferritin levels (36.87 ng/ml) than late preterm infants (65.78 ng/ml) at 3 months corrected age (p<0.05).
  • Higher birth weight correlated positively with ferritin levels, indicating its influence on iron metabolism.

Conclusions:

  • Postnatal iron supplementation (2-4 mg/kg/d) effectively lowers ID incidence in preterm infants.
  • Significant differences in iron levels exist between early and late preterm infants.
  • Tailored iron supplementation plans considering growth, birth weight, and gestational age are recommended.
Abstract

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...